Managing the intestinal carriage of APEC
Avian colibacillosis ranks as one of the most commonly encountered bacterial diseases in poultry worldwide and leads to considerable economic losses. Therefore, Wisium is investigating solutions to reduce APEC intestinal carriage.
Avian colibacillosis, an exclusively extra-intestinal disease is caused by a subgroup of pathogenic E. coli called Avian Pathogenic E. coli (APEC). APEC strains possess a variety of virulence factors that confer them the ability to survive and proliferate in the host outside of the gut environment where they normally reside. Being the main reservoir of APEC, the gastrointestinal tract of birds and resulting excreta play a critical role in APEC propagation. A common route of infection is inhalation of the faecally contaminated dust that contains large numbers of pathogenic E. coli. Infections by APEC typically result in severe respiratory and systemic diseases such as airsacculitis and septicemia or cause inflammations of internal organs membranes such as peritonitis, perihepatitis and pericarditis. They are also a threat to food security and avian welfare worldwide. Intensification of poultry production will increase the incidence of APEC through greater exposure of birds to pathogens and stress.
Combatting economic losses
Due to the versatility of the pathogeny of avian colibacillosis, APEC can be responsible for considerable economic losses affecting multi-species and multi-physiological stage poultry farming systems, while the regulatory environment is progressively further restricting the use of antibiotics in livestock animal in efforts to halt the spreading of bacterial resistance.
On the field, consequences of APEC infection for young broilers lead mainly to mortality. Reducing APEC intestinal carriage and faecal excretion could therefore contribute to the management of avian colibacillosis. In this context, the Wisium research and development (R&D) team is looking to evaluate the effect of a patented Copper-exchanged Clay (CeC) on APEC faecal excretion of chickens. The company has been working for almost 15 years to develop CeC, a unique and patented nutritional specialty aiming at securing digestive process, based on an ion activated clay bringing to the product high antimicrobial potency on various pathogens. Its specificity is to act as a microflora modulator in the gut and to help monogastric animals face challenging periods. CeC is backed up by scientific evidence: more than 60 trials are available which were run both in R&D and field conditions.
French trial results
A study was carried out at INRA experimental infectiology platform in France, using 22 day old chicks Leghorn PA 12. The birds were orally inoculated with a highly pathogenic APEC O2 strain. Faecal bacterial counts,...
Do you already have an account? Log in here